Abstract

You have accessJournal of UrologyAdrenal, Testis, UTUC Oncology & More1 Apr 2018V06-06 ROBOT-ASSISTED RETROPERITONEAL LYMPH NODE DISSECTION FOR ADVANCED TESTICULAR CANCER Akbar Ashrafi, Hatim Thaker, Inderbir Gill, and Hooman Djaladat Akbar AshrafiAkbar Ashrafi More articles by this author , Hatim ThakerHatim Thaker More articles by this author , Inderbir GillInderbir Gill More articles by this author , and Hooman DjaladatHooman Djaladat More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2018.02.1585AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Retroperitoneal lymph node dissection (RPLND) remains a cornerstone of management in advanced testicular carcinoma. Robotic approaches have emerged as an alternative to traditional open techniques. Potential advantages of minimally invasive approaches include reduced blood loss, perioperative morbidity and length of stay as well as faster convalescence and improved cosmesis. METHODS We reviewed our series of 5 consecutive patients undergoing robot-assisted RPLND for advanced testicular cancer (Stage IIA or higher). Data was collected on operative time, estimated blood loss, intra- and postoperative complications and pathological outcomes. RESULTS Median age was 22 (22-26). Three patients had primary RPLND for Stage IIA disease and two had post-chemotherapy RPLND for residual masses (see Video). Median (range) operating time and estimated blood loss was 360 minutes (270-400) and 50mL (10-100) respectively. None of the patients required intra- or post-operative transfusions. Median node count was 27 (18-40). Median positive node count was 3 (1-5). Median time to bowel recovery and length of stay was 1 day (1-2). There were 2 minor complications (chylous ascites managed with dietary modification and deep vein thrombosis) and no gastrointestinal, genitourinary or wound complications. There were no major complications or readmissions. There were no recurrences at 6 months follow-up. CONCLUSIONS Robotic-assisted RPLND is safe and feasible for advanced testicular cancer. Our data suggests that the robotic approach minimizes surgical morbidity and reduces length of hospital stay without compromising lymph node yield or early oncological outcomes. Further follow up is required to confirm this technique long-term oncological efficacy. © 2018FiguresReferencesRelatedDetails Volume 199Issue 4SApril 2018Page: e662 Advertisement Copyright & Permissions© 2018MetricsAuthor Information Akbar Ashrafi More articles by this author Hatim Thaker More articles by this author Inderbir Gill More articles by this author Hooman Djaladat More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call